By Richard Gale and Dr. Gary Null
Ivermectin was first introduced to the market in the early 1980s as an anti-parasitic drug for veterinary infections. However, its effectiveness was observed to be so remarkable and multifaceted that researchers started to investigate its potential for treating human diseases. In 1987, the FDA approved ivermectin for treating two parasitic diseases, river blindness and stronglyoidiasis, in humans.
Since then an enormous body of medical research has grown showing ivermectin’s effectiveness for treating other diseases. Its broad range antiviral properties has shown efficacy against many RNA viruses such avian influenza, zika, dengue, HIV, West Nile, yellow fever, chikungunya and earlier severe respiratory coronaviruses. It has also been found effective against DNA viruses such as herpes, polyomavirus, circovirus-2 and others. The drug is capable of modulating a host immune response during viral infections and reduces pro-inflammatory cytokines that contribute to viral tissue damage.
Unsurprisingly, its discovers Drs. William Campbell and Satoshi Omura were awarded the 2015 Nobel Prize in Physiology and Medicine. Ivermectin was not a drug simply hidden away in a back closet; rather it has been prescribed to hundreds of millions of people worldwide. Given its decades’ long record of in vitro efficacy, it should have been self-evident for Fauci, the CDC and the WHO to rapidly conduct in vivo trials to bring ivermectin into becoming a first line of defense for early stage Covid-19 infections and for use as a safe prophylaxis. For example, if funding were devoted for the rapid development of a micro-based pulmonary delivery system, mortality rates would have been miniscule and the pandemic would have been greatly lessened. Repurposing ivermectin could have been achieved very quickly at a minor expense.
However, despite all the medical evidence confirming ivermectin’s strong antiviral properties and its impeccable safety record when administered properly, we instead witnessed a sophisticated government-orchestrated campaign to declare war against ivermectin and another antiviral drug, hydroxychloroquine (HCQ), in favor of far more expensive and unproven experimental drugs, such as Remdesivir. U


